LivingGLP1
Study S002092

Efficacy and Safety of Low-Dose Semaglutide for Weight Loss and Cardiometabolic Improvement in Obese Pakistani Adults Without Type 2 Diabetes: A Single-Arm Open-Label Single-Center Trial

ClinicalTrials.gov record

Registration

Registration
NCT07513168
Study type
INTERVENTIONAL
Phase
PHASE4
Masking
NONE
Status
RECRUITING
Enrollment
60
Start
2025-08-01
Primary completion
2026-08-30
Lead sponsor
Asian Institute Of Medical Sciences
Conditions
Obesity; Weight Reduction; Cardiometabolic Risk Factors
Interventions
DRUG:Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)
Results posted
FALSE
Individual participant data sharing
YES

Registered primary outcomes

  • Percentage Change in Body Weight [Baseline to 24 weeks]

Linked records (20)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0008861Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss.
Sterckx M, Cureus
2026Case reportPMID 41773123DOIregistry reference BACKGROUND:41773123
R0000829Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.
Ismaiel A, International journal of obesity (2005)
2025Systematic reviewPMID 40804463DOIregistry reference BACKGROUND:40804463
R0003168Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.
Thomsen RW, Diabetes, obesity & metabolism
2025Randomized trialPMID 40196933DOIregistry reference BACKGROUND:40196933
R0003655Beyond Glycemic Control: Concurrent GLP-1 Receptor Agonist Use Is Associated with Reduced Urinary Adverse Events Following OnabotulinumtoxinA Treatment in Non-Diabetic Adults with Overactive Bladder.
Hammad MAM, Toxins
2025Nonrandomized studyPMID 41295856DOIregistry reference BACKGROUND:41295856
R0008457Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials.
Kasagga A, Cureus
2025Systematic reviewPMID 40978842DOIregistry reference BACKGROUND:40978842
R0006567Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.
Rodriguez PJ, JAMA internal medicine
2024Randomized trialPMID 38976257DOIregistry reference BACKGROUND:38976257
R0007442Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Moiz A, The American journal of cardiology
2024Systematic reviewPMID 38679221DOIregistry reference BACKGROUND:38679221
R0011954EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
European Association for the Study of the Liver (EASL), Journal of hepatology
2024OtherPMID 38851997DOIregistry reference BACKGROUND:38851997
R0018713Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Ryan DH, Nature medicine
2024Other trialPMID 38740993DOIregistry reference BACKGROUND:38740993
R0007316Semaglutide for the treatment of obesity.
Chao AM, Trends in cardiovascular medicine
2023Narrative reviewPMID 34942372DOIregistry reference BACKGROUND:34942372
R0011412Obesity Management in Adults: A Review.
Elmaleh-Sachs A, JAMA
2023Narrative reviewPMID 38015216DOIregistry reference BACKGROUND:38015216
R0012436Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity.
Quddos F, Scientific reports
2023Nonrandomized studyPMID 38017205DOIregistry reference BACKGROUND:38017205
R0015234Semaglutide for the treatment of overweight and obesity: A review.
Bergmann NC, Diabetes, obesity & metabolism
2023Other trialPMID 36254579DOIregistry reference BACKGROUND:36254579
R0013958Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G, Journal of investigative medicine : the official publication of the American Federation for Clinical Research
2022Nonrandomized studyPMID 34706925DOIregistry reference BACKGROUND:34706925
R0021582Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Tan HC, Journal of the ASEAN Federation of Endocrine Societies
2022Systematic reviewPMID 36578889DOIregistry reference BACKGROUND:36578889
R0021896Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Garvey WT, Nature medicine
2022Randomized trialPMID 36216945DOIregistry reference BACKGROUND:36216945
R0022757Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Wilding JPH, Diabetes, obesity & metabolism
2022Randomized trialPMID 35441470DOIregistry reference BACKGROUND:35441470
R0006087Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.
Ard J, Advances in therapy
2021Narrative reviewPMID 33977495DOIregistry reference BACKGROUND:33977495
R0013102Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D, JAMA
2021Randomized trialPMID 33755728DOIregistry reference BACKGROUND:33755728
R0023506Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Wadden TA, JAMA
2021Randomized trialPMID 33625476DOIregistry reference BACKGROUND:33625476